KPRX Kiora Pharmaceuticals Inc

On September 13, 2022 (the “Effective Date”), Kiora Pharmaceuticals Inc. (the “Company”) appointed Melissa Tosca as Executive Vice President of Finance of the Company, effective as of the Effective Date. Ms. Tosca will also serve as the Company’s principal accounting officer and principal financial officer.

Prior to joining the Company, Ms. Tosca, age 43, served as Executive Director of Finance and Corporate Treasurer for Neomorph since 2021, where she managed the finance and accounting functions. She also served as Director of Finance and Accounting at Omniome from 2017 to 2021, building the accounting and finance infrastructure and managing financial operations. Prior to Omniome, she spent nine years at Caris Life Sciences from 2008 to 2017, serving in various leadership roles including Director of Finance and Accounting, Director of Financial Planning and Analysis and Senior Director of Sales Operations. She began her professional career in public accounting at Clifton Gunderson and later moved to Ernst & Young as an Audit Manager. Melissa is a Certified Public Accountant and holds a B.S. in Accounting from the University of Arizona.

In connection with Ms. Tosca’s appointment as Executive Vice President of Finance, the Company entered into an Offer Letter (the “Offer Letter”) with Ms. Tosca on August 18, 2022 and effective as of the Effective Date. Pursuant to the Offer Letter, Ms. Tosca will receive an annual base salary of  $300,000 and she is entitled to receive a performance bonus with a target of up to 25% of her annual base salary for the applicable fiscal year. Additionally, subject to the approval of the Compensation Committee of the Company’s Board of Directors and shareholder approval of an increase in the shares authorized for issuance under the Company’s 2014 Equity Incentive Plan, the Company will grant Ms. Tosca an option to purchase up to 300,000 shares of the Company’s common stock (the “Option”). The Option will vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date, and thereafter will vest in equal monthly installments over a two-year period.

There is no family relationship between Ms. Tosca and any director or executive officer of the Company. There are no transactions between Ms. Tosca and the Company that would be required to be reported under Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended.

The foregoing summary of the material terms of the Offer Letter does not purport to be complete and is subject to, and qualified in its entirety by, the full and complete terms of the Offer Letter, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.